Systemic Antipsoriatic Drug Development Services

At Ace Therapeutics, we understand the challenges associated with developing effective systemic therapies for psoriasis. Our systemic sntipsoriatic drug development services are designed to support researchers and organizations in their quest to develop innovative therapeutics that effectively target the underlying mechanisms of psoriasis.

Introduction to Systemic Drugs for Psoriasis

Psoriasis is driven by a dysregulated immune response, primarily involving proinflammatory cytokines such as IL-17, IL-23, and TNF-α. These cytokines play crucial roles in the psoriatic immune cascade, leading to the activation of various immune cells and resulting in the hallmark symptoms of the disease. Recent advancements in understanding these mechanisms have led to targeted therapies, particularly systemic options for moderate to severe psoriasis when topical treatments are inadequate. Current systemic options include innovative biologics, such as monoclonal antibodies targeting specific cytokines (e.g., IL-17 inhibitors and IL-23 inhibitors), and small-molecule drugs like apremilast, which modulate intracellular pathways. These therapies provide effective, long-lasting interventions.

Fig. 1 Therapies for cutaneous psoriasis. (Yan BX, et al., 2021)

Comprehensive Systemic Antipsoriatic Drug Development Services

At Ace Therapeutics, we provide a comprehensive range of preclinical services designed to support the development of systemic antipsoriatic drugs.

Target Identification and Validation

• Bioinformatics Analysis: Utilizing advanced bioinformatics tools to identify and validate novel therapeutic targets relevant to psoriasis.
• Pathway Analysis: Conducting thorough analyses of inflammatory pathways to identify critical targets for therapeutic exploration.

In Vitro Assays

• Cell Culture Models: Implementing studies using human keratinocyte cell lines (e.g., HaCaT) to evaluate effects on cell proliferation and viability.
• Cytotoxicity Assessments: Conducting assays such as the MultiTox-Glo Multiplex Cytotoxicity Assay to measure live and dead cells, providing insights into the safety profiles of drug candidates.
• Inflammatory Response Evaluation: Analyzing cytokine production and gene expression changes to evaluate anti-inflammatory efficacy using quantitative PCR and ELISA.

In Vivo Efficacy Studies

• Animal Models of Psoriasis: Utilizing animal models, such as the imiquimod-induced psoriasis model, to assess the therapeutic efficacy of systemic agents.
• Histopathological Analysis: Conducting detailed histological examinations to evaluate the effects of drug candidates on skin morphology, inflammation levels, and keratinocyte behavior.

Formulation Development Support

• Formulation Optimization: Providing expertise in developing optimized formulations for systemic delivery, including both oral and intravenous routes to improve bioavailability and therapeutic effectiveness.
• Stability Testing: Performing stability studies to evaluate the integrity and efficacy of drug formulations over time under various conditions.

The development of effective systemic therapies for psoriasis requires a nuanced understanding of the mechanisms of diseases and therapeutic targets. At Ace Therapeutics, we are dedicated to offering extensive preclinical services that facilitate drug development and support the discovery of innovative systemic therapies for psoriasis. Contact us today to learn more about how we can support your drug development projects.